相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjogren's syndrome: A systematic review from the Italian Society of Rheumatology
Gianluca Sambataro et al.
AUTOIMMUNITY REVIEWS (2020)
Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review
Mattia Bellan et al.
AUTOIMMUNITY REVIEWS (2020)
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
Camelia Frantz et al.
AUTOIMMUNITY REVIEWS (2020)
Challenges in the treatment of Rheumatoid Arthritis
Paola Conigliaro et al.
AUTOIMMUNITY REVIEWS (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Interstitial lung disease associated with anti-PM-Scl antibody: A single center experience
Kamonpun Ussavarungsi et al.
AUTOIMMUNITY REVIEWS (2019)
Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides
Gwen E. Thompson et al.
CLINICS IN CHEST MEDICINE (2019)
Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis
Thomas Barba et al.
AUTOIMMUNITY REVIEWS (2019)
Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays
Jan Damoiseaux et al.
AUTOIMMUNITY REVIEWS (2019)
Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases
Isabel Mira-Avendano et al.
MAYO CLINIC PROCEEDINGS (2019)
Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review
Fabiola Atzeni et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Imaging aspects of interstitial lung disease in patients with rheumatoid arthritis: Literature review
Alexandra Balbir-Gurman et al.
AUTOIMMUNITY REVIEWS (2018)
Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review
Mathilde Thiebaut et al.
AUTOIMMUNITY REVIEWS (2018)
What's in a name? That which we call IPF, by any other name would act the same
Athol U. Wells et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF)
Ivo A. Wiertz et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review
Tracy J. Doyle et al.
JOURNAL OF RHEUMATOLOGY (2018)
Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment
You-Jung Ha et al.
BIOMED RESEARCH INTERNATIONAL (2018)
The Lung in Rheumatoid Arthritis Focus on Interstitial Lung Disease
Paolo Spagnolo et al.
ARTHRITIS & RHEUMATOLOGY (2018)
How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study
Christos F. Kampolis et al.
AUTOIMMUNITY REVIEWS (2018)
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
Ana Catarina Duarte et al.
CLINICAL RHEUMATOLOGY (2018)
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
Toby M. Maher et al.
BMJ OPEN RESPIRATORY RESEARCH (2018)
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
Peter Saunders et al.
TRIALS (2017)
Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial
Juergen Behr et al.
BMC PULMONARY MEDICINE (2017)
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts
Yoel Brito et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome
Simon J. Bowman et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Interstitial lung disease in primary Sjogren's syndrome
F. Roca et al.
AUTOIMMUNITY REVIEWS (2017)
Lung Manifestations in the Rheumatic Diseases
Tracy J. Doyle et al.
CHEST (2017)
How I treat patients with systemic sclerosis in clinical practice
Daniela Rossi et al.
AUTOIMMUNITY REVIEWS (2017)
Design of the PF-ILD trial: a doubleblind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
Kevin R. Flaherty et al.
BMJ OPEN RESPIRATORY RESEARCH (2017)
Interstital lung disease in ANCA vasculitis
Marco A. Alba et al.
AUTOIMMUNITY REVIEWS (2017)
Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease
Cheilonda Johnson
CURRENT OPINION IN RHEUMATOLOGY (2017)
Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease
Dong Jin Go et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Systemic sclerosis: An update in 2016
Anne Claire Desbois et al.
AUTOIMMUNITY REVIEWS (2016)
Pulmonary involvement in systemic sclerosis
Adriana Morales-Cardenas et al.
AUTOIMMUNITY REVIEWS (2016)
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease Our interdisciplinary rheumatology-pneumology experience, and review of the literature
Clodoveo Ferri et al.
AUTOIMMUNITY REVIEWS (2016)
Management of connective tissue diseases associated interstitial lung disease: a review of the published literature
Beth Wallace et al.
CURRENT OPINION IN RHEUMATOLOGY (2016)
Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome
Divi Cornec et al.
JOURNAL OF AUTOIMMUNITY (2016)
Update on the pharmacological treatment of adult myositis
C. V. Oddis
JOURNAL OF INTERNAL MEDICINE (2016)
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2016)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study
Mitsuhiro Akiyama et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Management of interstitial lung disease associated with connective tissue disease
Stephen C. Mathai et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Management of interstitial lung disease associated with connective tissue disease
Stephen C. Mathai et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?
Michele Iudici et al.
AUTOIMMUNITY REVIEWS (2015)
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature
Dilia Giuggioli et al.
AUTOIMMUNITY REVIEWS (2015)
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis
Silvia L. Bosello et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor a agents, a retrospective cohort study
Jeffrey R. Curtis et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Suzana Jordan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis
Takashi Kurita et al.
RHEUMATOLOGY (2015)
Treatment of Primary Sjogren Syndrome With Rituximab A Randomized Trial
Valerie Devauchelle-Pensec et al.
ANNALS OF INTERNAL MEDICINE (2014)
AB0800 Safety and clinical response to rituximab in patients with connective tissue disease-associated interstitial lung disease: Preliminary results
F.I. Romero et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
FRI0228 Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement
E. Becerra et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review
Michael Mahler et al.
AUTOIMMUNITY REVIEWS (2014)
Abatacept Therapy in Rheumatoid Arthritis With Interstitial Lung Disease
Antonio Mera-Varela et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2014)
Rituximab in severe, treatment-refractory interstitial lung disease
Gregory J. Keir et al.
RESPIROLOGY (2014)
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Paolo Fraticelli et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis
Tamao Nakashita et al.
BMJ OPEN (2014)
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
Jacques-Eric Gottenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis
Benedetta Marigliano et al.
AUTOIMMUNITY REVIEWS (2013)
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
Michael E. Weinblatt et al.
JOURNAL OF RHEUMATOLOGY (2013)
Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease
Aryeh Fischer et al.
JOURNAL OF RHEUMATOLOGY (2013)
Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience
Yolanda Braun-Moscovici et al.
RHEUMATOLOGY INTERNATIONAL (2013)
Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review
Dan Chen et al.
RHEUMATOLOGY INTERNATIONAL (2013)
Interstitial Lung Disease in AntiJo-1 Patients With Antisynthetase Syndrome
I. Marie et al.
ARTHRITIS CARE & RESEARCH (2013)
Topical and systemic medications for the treatment of primary Sjogren's syndrome
Manuel Ramos-Casals et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome
I. Marie et al.
RESPIRATORY MEDICINE (2012)
Non-infectious pulmonary toxicity of rituximab: a systematic review
Andreas V. Hadjinicolaou et al.
RHEUMATOLOGY (2012)
A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab
Shin-ya Kawashiri et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab
Jin-Kyoung Park et al.
RHEUMATOLOGY INTERNATIONAL (2012)
The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study
M. O. Becker et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
Takao Koike et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
Robert F. Spiera et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
A One-Year, Phase I/IIa, Open-Label Pilot Trial of Imatinib Mesylate in the Treatment of Systemic Sclerosis-Associated Active Interstitial Lung Disease
Dinesh Khanna et al.
ARTHRITIS AND RHEUMATISM (2011)
Short-Term and Long-Term Outcomes of Interstitial Lung Disease in Polymyositis and Dermatomyositis A Series of 107 Patients
I. Marie et al.
ARTHRITIS AND RHEUMATISM (2011)
Interstitial lung disease in systemic sclerosis
Guillaume Bussone et al.
AUTOIMMUNITY REVIEWS (2011)
Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy
Jun Wei et al.
AUTOIMMUNITY REVIEWS (2011)
Therapy of polymyositis and dermatomyositis
Isabelle Marie et al.
AUTOIMMUNITY REVIEWS (2011)
Biological treatments and connective tissue disease associated interstitial lung disease
Stylianos T. Panopoulos et al.
CURRENT OPINION IN PULMONARY MEDICINE (2011)
Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review
Andreas V. Hadjinicolaou et al.
RHEUMATOLOGY (2011)
Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade
M. Mohr et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2011)
Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases
Roberto Perez-Alvarez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Dimitrios Daoussis et al.
RHEUMATOLOGY (2010)
Mycophenolate Mofetil for Interstitial Lung Disease in Dermatomyositis
Pamela A. Morganroth et al.
ARTHRITIS CARE & RESEARCH (2010)
Rituximab treatment of the anti-synthetase syndrome-a retrospective case series
Marthe Sem et al.
RHEUMATOLOGY (2009)
Rituximab in life threatening antisynthetase syndrome
E. Vandenbroucke et al.
RHEUMATOLOGY INTERNATIONAL (2009)
Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug
Lcslcy Ann Saketkoo et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Effects of 1-year treatment with CycNophosphamilde on outcomes at 2 years in scleroderma lung disease
Donald P. Tashkin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20)
Valerie Devauchelle-Pensec et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome
Raphaele Seror et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome
D Paran et al.
AUTOIMMUNITY REVIEWS (2004)
Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis
E Bargagli et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
分享论文
